TRAVERE THERAPEUTICS, INC. Development Stage Enterprise, Deficit Accumulated During Development Stage (Deprecated 2015-01-31)
TRAVERE THERAPEUTICS, INC. (TVTX) had Development Stage Enterprise, Deficit Accumulated During Development Stage (Deprecated 2015-01-31) of $129.58 million as of 2014-06-30, per its 10-Q filed 2014-08-14.
Discontinued › Notes
us-gaap:DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage · last filed 2014-08-14
- 2014-06-30: Development Stage Enterprise, Deficit Accumulated During Development Stage (Deprecated 2015-01-31) $129.58M.
- 2014-03-31: Development Stage Enterprise, Deficit Accumulated During Development Stage (Deprecated 2015-01-31) $138.06M.
- 2013-12-31: Development Stage Enterprise, Deficit Accumulated During Development Stage (Deprecated 2015-01-31) $67.44M.
- 2013-09-30: Development Stage Enterprise, Deficit Accumulated During Development Stage (Deprecated 2015-01-31) $54.30M.
| Period end | Development Stage Enterprise, Deficit Accumulated During Development Stage (Deprecated 2015-01-31) |
|---|---|
| 2014-06-30 | $129.58M 10-Q · filed 2014-08-14 |
| 2014-03-31 | $138.06M 10-Q · filed 2014-05-15 |
| 2013-12-31 | $67.44M 10-Q · filed 2014-08-14 |
| 2013-09-30 | $54.30M 10-Q · filed 2013-11-13 |
| 2013-06-30 | $43.40M 10-Q · filed 2013-09-16 |
| 2013-03-31 | $38.36M 10-Q/A · filed 2013-09-16 |
| 2012-12-31 | $33.61M 10-K · filed 2014-03-28 |
| 2011-12-31 | $3.27M 10-K/A · filed 2013-09-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |